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Abstract 
Aim: To evaluate the effects of a preventive antioxidant treatment of streptozotocin 
(STZ)-diabetic rats with epigallocatechin gallate (EGCG) in oxidative stress 
damage and neuronal activation at the spinal cord and in behavioural signs of 
diabetic neuropathic pain (DNP). 
Materials and Methods: Three days after STZ injection, the rats initiated a 
treatment protocol with an aqueous solution of EGCG (2g/L) in the drinking water 
during 10 weeks. Mechanical nociception was evaluated before and after EGCG 
treatment using the paw-pressure and von Frey tests. Spinal cords were 
immunoreacted against 8-hydroxy-2’-deoxyguanosine (marker of oxidative stress 
damage; 8-OHdG), and double immunoreacted against 8-OHdG and Fos (marker 
of neuronal activation). 
Results: STZ rats presented increased oxidative stress damage (immunodetection 
of 8-OHdG) and higher activation of nociceptive spinal neurons (immunodetection 
of Fos protein), with a contingent of 8-OHdG-positive neurons also expressing Fos 
than in age-matched controls. In these animals mechanical hyperalgesia (paw-
pressure test) and tactile allodynia (von Frey test) were higher than in controls. 
Treatment with EGCG normalized oxidative stress and neuronal activation to 
control levels and ameliorated behavioral mechanical nociceptive responses. 
Conclusions: The beneficial effects of the preventive antioxidant treatment with 
EGCG at the spinal cord and behavioral signs of DPN indicate that early detection 
of diabetes allows the onset of antioxidant treatment that can prevent oxidative 
stress-induced damage to the somatossensory system. 
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Introduction 
Oxidative stress is one of the most prominent features of diabetes and has been 
implicated in the pathophysiological changes underlying several complications of 
the disease [1]. Diabetic neuropathy is the most common complication of the 
disease, affecting approximately 50% of the patients, 10-26% of which complain of 
pain [2,3]. Diabetic neuropathic pain (DNP) has complex manifestations, such as 
spontaneous pain, allodynia (increased responses to innocuous stimuli), 
hyperalgesia (increased responses to innocuous stimuli) and paresthesias 
(sensation of tingling, tickling, prickling, or burning) [3].  Diabetes-induced 
oxidative stress accounts for DNP since massive oxidative stress damage has 
been reported in areas of the somatossensory system involved in the transmission 
of nociceptive input, namely peripheral nerves and spinal cord [4-6]. Furthermore, 
antioxidant treatment of diabetic animals reverts oxidative stress damage and 
behavioural signs of DNP [4]. In the clinical setting, adjuvant treatment of diabetic 
patients with antioxidants has raised some controversy, with both positive and 
negative outcomes reported [7]. 
The spinal cord, the first relay in the transmission of nociceptive input from the 
periphery to the brain, is affected by diabetes in humans and animal models. 
Structural and functional abnormalities have been identified at the spinal cord of 
diabetic patients [8,9]. An increased baseline activity of nociceptive neurons has 
been reported in the spinal cord of streptozotocin-induced diabetic rats (STZ-
diabetic rats). Hyperactivity affected neurons occurring in the superficial laminae of 
the spinal dorsal horn, which participate in transmission of nociceptive input to the 
brain [10,11]. Diabetes-induced oxidative stress is likely to account to the neuronal 
hyperactivity at the spinal cord.  In models of traumatic neuropathy, decreasing the 
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levels of reactive oxygen species (ROS) at the spinal cord reduced behavioural 
signs of pain and restored normal neuronal activity [12,13]. Due to the high 
oxidative stress damage in the spinal cord during diabetic neuropathy, it is 
important to evaluate if preventing the appearance of oxidative stress in the spinal 
cord of STZ-diabetic rats would also have a beneficial effect in neuronal 
hyperactivity and DNP. 
We recently used an animal model of diabetes, the STZ-diabetic rat, to study the 
value of an antioxidant treatment in managing DNP. Starting a 2 week treatment of 
STZ rats with 4 weeks duration of diabetes, with intraperitoneal administrations of 
!-lipoic acid reversed oxidative stress damage and neuronal hyperactivity at the 
spinal cord to the level of non-diabetic animals [4]. Although this also improved 
behavioural signs of DNP accessed by increased sensitivity to noxious mechanical 
stimuli (mechanical hyperalgesia), a normalization to control levels was not 
achieved [4]. Since increased responses to innocuous stimuli (mechanical 
allodynia) were not evaluated and this is a more clinically relevant sign of DNP [9], 
it remains to ascertain the putative translational application of antioxidants. 
Epigallocatechin-gallate (EGCG), the major catechin present in green tea, has a 
similar efficacy when compared with !-lipoic acid in protecting cellular DNA from 
ROS but has a much higher potency in reducing lipid peroxidation [14,15]. The 
utility of EGCG in the clinical setting has been demonstrated in several studies, 
namely in diabetes type 1 by decreasing the risk of its development through 
several antioxidative and anti-inflammatory actions in a variety of cell types 
[16,17]. EGCG is an antioxidant particularly indicated for studies of the spinal cord 
since it crosses the blood-brain barrier and promotes neuronal recovery after 
spinal cord injury even using a systemic administration route [18,19]. The 
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mechanisms of action of EGCG are complex and include ROS removal, increase 
of anti-oxidant enzymes, chelation of transitional metals, modulation of apoptotic 
pathways and increased expression of neurotrofic factors [17]. Based on the 
above summarized findings [4], using !-lipoic acid treatment of STZ-diabetic rats 
after the disease is fully established (4 weeks of diabetes), we hypothesize that 
using EGCG in STZ-diabetic rats with long term diabetes (10 weeks) and 
anticipating the onset of treatment to the moment of hyperglycaemia appearance 
should have a higher effect in behavioural signs of DNP. We further aim to 
evaluate if oxidative stress damage affects spinal neurons activated by nociceptive 
stimuli and whether this is could be corrected by the preventive EGCG treatment. 
 
 
Materials and methods 
 
Animals 
Adult male Wistar rats weighing 250-300g at the beginning of the experiments 
were housed twice per cage in a room with a constant temperature (22±2ºC) and 
humidity (55±5%) with a 12h light/dark cycle, and received food and water ad 
libitum. Experiments were performed in accordance with the European Community 
Council directive 86/609/EEC and the ethical guidelines for the study of pain in 
conscious animals [20]. 
 
Induction of Diabetes 
Type 1 diabetes was induced in 16 rats by an intraperitoneal (i.p) injection of STZ 
(60mg/kg body weight; Sigma-Aldrich, Barcelona, Spain) dissolved in 0.1 M citrate 
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buffer (pH 4.5). Control animals (n=8) received an i.p injection of the same citrate 
buffer. Three days later, glucose levels were measured in a blood sample 
collected from the tail vein using Accu Chek Sensor Comfort (Roche Diagnostics, 
Berlin, Germany). Only rats with glucose levels above 270 mg/dl were considered 
diabetic [21]. Glucose levels were also measured at 4 and 10 weeks post-diabetes 
induction. 
 
Treatment protocol 
Three days after the injection of STZ or citrate buffer, a group of STZ-diabetic rats 
(n=8) initiated the treatment protocol with an aqueous solution of EGCG (2g/L; 
Holliday & Co, Canada) in the drinking water. The treatment lasted for 10 weeks 
and these animals formed the “STZ+EGCG group”. Non-diabetic animals (n=8) 
and the remaining SZT-diabetic rats (n=8) received water without EGCG, forming 
the “Control group” and the “STZ group”, respectively.  Liquid intake was daily 
measured and the animals were weakly weighted. 
 
Behavioral evaluation  
Mechanical hyperalgesia and tactile allodynia were assessed prior and 10 
weeks after STZ or vehicle injections using the paw-pressure and the von Frey 
tests, respectively. Both mechanical hyperalgesia and tactile allodynia are 
validated behavioural signs in STZ-diabetic rats [21]. All animals were daily 
handled during the 8 days preceding the behavioural analysis for habituation 
purposes. The behavioural evaluation was performed before diabetes inductions 
(week 0), and at the end of treatment (week 10). 
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 In the paw-pressure test, an increasing pressure was applied onto the 
dorsal surface of the right hindpaw with a cone-shaped plunger using the Randall-
Selitto device (Ugo Basile, Italy). The paw withdrawal threshold (PWT) was 
defined as the force, in grams, that elicited a detectable paw withdrawal. For the 
von Frey test, the animals were placed in clear acrylic boxes with a metal grid floor 
and acclimatized for 15 min before testing using an electronic device (Bioseb, 
France). A linearly increasing force (2,5 g/s) was applied to the plantar surface of 
the rat hindpaw with a filament (0.5mm). As for paw-pressure test, PWT was 
settled as the force inducing paw withdrawal. For both tests, the PWT for each 
animal was calculated as the average of three consecutive measurements with at 
least a 5 min interval between them.  
 
Sacrifice of the animals 
Ten weeks after the onset of treatment, the animals were deeply anesthetized with 
an i.p. injection of sodium pentobarbital (60 mg/kg body weight) and sacrificed by 
transcardiac vascular perfusion. Animal sacrifice was performed at least 30 
minutes after the last behavioral evaluation. Vascular transcardic perfusion was 
performed using 200ml of phosphate-buffered saline (PBS) followed by 1000 ml of 
4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB), pH 7.4 [4]. The 
spinal segments L4-L5 were removed, post-fixed for 2-4h in 4% PFA and 
cryoprotected overnight in 30% sucrose in 0.1 PBS at 4ºC. Transverse sections, 
40 !m thick were obtained using a freezing microtome, collected in 0.1 PBS. One 
in every 4 sections was processed for immunodetection of 8-hydroxy-2’-
deoxyguanosine (8-OHdG), a marker of oxidative stress damage of nucleic acid 
[22]. An additional set of sections was immunoreacted for 8-OHdG combined with 
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immunoreaction for Fos, a protein synthetized at the spinal cord when the Fos 
protooncogene is activated by nociceptive stimuliat the spinal cord neurons [23].  
 
Immunohistochemistry against 8-OHdG 
The sections used in the immunodetection of 8-OHdG were pretreated with 2 N 
HCl during 10 min to denature nucleic acids, followed by 5 min immersion in Tris-
base 1 M, as described previously [4]. All sections were treated with 1% hydrogen 
peroxide for 20 min to inhibit endogenous peroxidase activity before incubation for 
2h in a blocking solution containing 10% normal swine serum in 0.3% Triton X 
25% in PB (PBST). The sections were then incubated during two overnights at 4ºC 
in mouse anti-8-OHdG (1:1200; Trevigen, USA). After being washed in PBST, the 
sections were incubated in biotinylated rabbit anti-mouse (1:200; Dako, Denmark) 
immunoglobulin for 1h. Sections were then washed in PBST, incubated for 1h in 
the avidin-biotin-complex (Vectastain, Vector Lab, USA) and stained with 
diaminobenzidine (DAB). Sections were mounted on gelatine-coated slides, air 
dried and coverslipped with xylol. After observation under a light microscope, the 
images were acquired using a high resolution digital camera coupled to a 
computer. Immunolabelling for 8-OHdG was quantified by densitometric analysis 
of the superficial layers of the spinal dorsal horn (laminae I-III). A bilateral analysis 
was performed using the ImageJ software (National Institutes of Health, USA). 
The results are presented in optical units, as described previously [4].  
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Immunofluorescence against 8-OHdG and Fos 
In order to assess oxidative stress damage in spinal neurons activated by 
nociceptive stimuli, a double immunofluorescence reaction was performed in the 
additional set of spinal sections. These sections were treated with 1% borohydrate 
for 20min, before incubation in a blocking solution containing 10% normal horse 
serum (NHS) in PBST with 0.1 M glycine, for 2h.  Sections were then incubated 
during 2 overnights at 4ºC in a mixture of a mouse anti-8-OHdG (1:500; Trevigen, 
Gaithersburg, MD, USA) and a rabbit anti-Fos (1:1000; Ab5; Oncogene, Germany) 
antibody in a 2% NHS solution. After being washed in a 2% NHS in PBST solution, 
the sections were incubated for 1h at room temperature, in a mixture of two 
fluorescent antibodies: goat anti-mouse Alexa 594 and goat anti-rabbit Alexa 488, 
both at 1:500 (Molecular Probes, USA), in a 2% NHS in PBST solution. Sections 
were examined using an ApoTome microscope (Zeiss, Germany) and the images 
acquired using a high-resolution camera coupled to a computer. Merged images 
were obtained using the ApoTome software. The numbers of neurons 
immunoreactive (IR) for 8-OHdG, for Fos or both were bilaterally counted in the 
superficial dorsal horn (laminae I-III).  The percentages of 8-OHdG-IR neurons that 
were also Fos-IR were counted. The specificities of primary antibodies against 8-
OHdG and Fos were previously demonstrated [4]. 
 
Statistical Analysis 
SPSS Statistics version 18 (IBM, Armonk, New York, USA) was used for 
statistical analysis. Means were compared by ANOVA followed by Tukey post hoc 
test for multiple comparisons. Statistical significance was settled as p<0.05. 
Results are presented as mean ± SEM. 
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Results 
 
1- Metabolic characterization  
All STZ rats developed hyperglycaemia within 3 days post-injection, which was 
maintained during the time of the experiments, when compared with the non-
diabetic age matched controls (Table 1). The STZ group presented a lower body 
weight and increased liquid intake in comparison to controls (Table 1). The 
treatment with EGCG did not affect blood glucose concentration, body weight or 
liquid intake when comparing with STZ-diabetic rats (Table 1). Mean EGCG 
consumption per day was 494±13.8 mg, indicating a low heterogeneity within the 
treated group.  
 
2- Effects of EGCG on mechanical nociception  
The PWTs in STZ rats were significantly reduced both in the paw-pressure test 
(Fig. 1A) and von Frey (Fig. 1B) test in comparison with baseline values and the 
control group. These results confirm the development of mechanical hyperalgesia 
(Fig. 1A) and tactle allodynia (Fig. 1B) at 10 weeks of diabetes in the STZ-diabetic 
rat model [11]. The STZ+EGCG group presented higher PWTs both in the paw-
pressure (Fig. 1 A) and in the von Frey (Fig. 1 B) tests, when compared with 
values of untreated STZ rats, indicating an amelioration of mechanical 
hyperalgesia and tactile allodyinia, respectively. The effects of EGCG in 
mechanical hyperalgesia appear to be stronger than in tectile allodynia since those 
differences were more pronounced in the paw-pressure test than in the von Frey 
test (cf. Figs 1A and 1B). These data indicate that EGCG treatment has a 
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preventive effect on mechanical nociceptive responses detected in STZ-diabetic 
rats.  
 
3- Effects of EGCG at 8-OHdG expression at spinal cord 
Cells IR for 8-OHdG were identified by a diffuse punctate pattern distributed over 
the nucleus and cytoplasm which reflects both nuclear and mitochondrial DNA 
damage [22], as shown in the inset of Fig. 2C.   
As shown in Fig. 2, untreated STZ rats presented a significant increase in the 
expression of 8-OHdG in comparison with the control group (STZ versus Control: 
p=0.013). The treatment with EGCG prevented the increase of 8-OHdG, with 
statistically significant differences between STZ+EGCG and STZ group (p=0.033).  
A complete normalization of 8-OHdG expression was obtained after EGCG 
treatment since 8-OHdG expression in the STZ+EGCG group was similar to the 
control group (p=0.833). 
 
4- Effects of EGCG at Fos expression at the spinal cord 
Fos-IR neurons were recognized by the stained nucleus (Fig 3 B-C). The number 
of Fos-IR neurons was significantly higher in the STZ group when compared with 
the control group (STZ versus Control: p=0.017) (Fig 3 A). The treatment with 
EGCG prevented the increased numbers of Fos-IR neurons in the spinal cord of 
STZ rats, with statistically significant differences between STZ+EGCG and STZ 
groups (p=0.037). A complete normalization of Fos expression was obtained after 
EGCG treatment since the number of Fos-IR neurons in the STZ+EGCG group 
was similar to the control group (STZ+EGCG versus Control: p= 0.875). 
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5- Effects of EGCG at the co-localization of 8-OHdG and Fos  
Neurons double-labelled for 8-OHdG and Fos were identified by the diffuse red 
punctate pattern surrounding the green immunorreaction of the nucleus (Fig. 4B-
D).  
The percentage of 8-OHdG-IR cells that were also Fos-IR in the STZ group was 
higher than in the control group (fig 4A). In the STZ, from an average number of 
163,33 neurons that were  8-OHdG-IR, 20% were shown to also co-localize for 
Fos. In the control group, from an average number of 117,79 neurons that were  8-
OHdG-IR, only 5% were shown to also co-localize for Fos. The treatment with 
EGCG prevented the increased co-localization of 8-OHdG and Fos, with 
statistically significant differences between STZ+EGCG and STZ group (p=0.037). 
In the STZ+EGCG group, from an average number of 96,71 neurons that were  8-
OHdG-IR, only 8% were shown to also co-localize for Fos. 
 
Discussion 
The present study shows, for the first time, that an antioxidant treatment with 
EGCG initiated as soon as hyperglycaemia induced-diabetes is detected can 
prevent the long-term effects of the disease at the spinal cord, namely oxidative 
stress damage and neuronal hyperactivity. The study also shows that the current 
EGCG treatment protocol can ameliorate behavioural signs of DNP. The early 
intervention protocol with an antioxidant is important, inasmuch that clinical trials 
using antioxidants have given contradictory results, probably because the 
treatments are usually initiated when the disease is fully established and oxidative 
stress damage is prominent [1, 7, 24]. In support of this hypothesis, it has been 
shown that oxidative stress increases gradually during the course of diabetes and 
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that preventive antioxidant treatments are more effective that curative protocols 
[25-27]. 
Treatment of diabetic rats with EGCG normalized oxidative stress damage 
and neuronal hyperactivity at the spinal cord to the levels of non-diabetic controls. 
It is likely that these findings are related since EGCG treatment is known to 
normalize the levels of ROS [28,29]. In traumatic neuropathic pain models, it was 
shown that excessive levels of ROS at the spinal cord are associated with 
enhanced activation of receptors involved in excitatory neurotransmission and loss 
of inhibitory GABAergic transmission [13,30]. It is therefore likely that the 
increased oxidative stress accounts for the higher neuronal activity detected in the 
spinal cord of diabetic rats. The normalization of signs of oxidative stress damage 
and of neuronal hyperactivity by the EGCG treatment was not accompanied by a 
full reversal of the analyzed behavioural signs of DNP. The magnitudes of EGCG-
induced improvement of behavioral signs of mechanical responses were slightly 
higher in the paw pressure test (mechanical hyperalgesia) than in the von Frey 
test (tactile allodynia), which refutes our initial hypothesis that tactile allodynia, a 
more clinically relevant sign of diabetes, is more prone to antioxidant treatment. 
Curiously, amelioration but not a complete normalization of behavioural responses 
to mechanical nociception was also detected after EGCG intrathecal delivery in 
traumatic neuropathic pain models [31,32]. Collectively, the results suggest that 
both in diabetic and traumatic neuropathic pain models, mechanisms besides the 
oxidative stress affecting the spinal cord are involved in behavioural pain 
responses.  
In the present study we used a treatment protocol with EGCG in the drinking water 
to evaluate the effects of this physiological approach. Supporting an action of 
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EGCG at the central nervous system, it was previously shown that this antioxidant 
crosses the blood brain barrier and that one of its main targets is the spinal cord 
[18,33]. We cannot exclude, however that EGCG also acts in other central nervous 
system areas, since we recently shown that a similar EGCG protocol treatment 
reverts oxidative stress-induced neurodegenerative changes in pain control 
centers of the brainstem [34]. 
By performing a co-localization of a marker of oxidative stress damage (8-OHdG) 
and a marker of neuronal activation (Fos) our study shows for the first time that at 
least 20% of the cells affected by oxidative stress at the spinal cord during 
diabetes are neurons. This conclusion is based on the fact that all Fos-IR cells are 
neurons [11]. That percentage is underestimated since some spinal cord neurons 
exhibiting oxidative stress signs probably expressed the Fos protein bellow 
detection levels or are not activated by nociceptive stimuli. Co-localization of 8-
OHdG with pan-neuronal markers, like Neu-N, will allow to enlighten this issue. 
Another interesting possibility is related to the interplay of oxidative stress and glial 
cells [35]. It has been demonstrated that the spinal cord of diabetic rats presents 
increased microglial activation [36]. We will evaluate if the preventive EGCG 
protocol used in the present study also prevents microglia activation and if the 
inhibition of microglia with intrathecal delivery of specific microglia inhibitors 
prevents oxidative stress damage. 
It should be noted that the beneficial effects of EGCG in STZ rats are not due to 
glyceamic normalization as our STZ+EGCG animals remained hyperglyceamic, at 
the timepoints measured (4 and 10 weeks after diabetes induction). These data 
are in accordance with the literature that shows that in type 1 diabetes an 
improvement of the hyperglycaemic condition occurs after EGCG treatment but 
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the reduction of hyperglycaemia is only achieved using higher EGCG 
concentrations than those used in the present protocol [37,-39]. Furthermore, a 
study in type 1 diabetes shows that the efficacy of EGCG in normalizing 
hyperglyceamia only occurs after longer treatment periods [40]. These conditions 
were elected in our experimental design since we wanted to evaluate only the 
effects of correcting the oxidative stress damage without the confounding effect of 
normalizing glycaemia. The beneficial effects of EGCG antioxidant treatment in 
amelioration of behavioural signs of diabetic neuropathy match data with other 
antoxidants, namely !-lipoic acid [4], resveratrol [41] and vitamin E [42]. These 
results obtained in animal models are, however, yet difficult to translate from 
bench to bedside since antioxidant treatments are frequently initiated when 
diabetes is already fully installed. Using protocols of EGCG treatment in early 
phases of diabetes has better outcomes in other complications of the disease, 
such as diabetic nephropathy [38], diabetic retinopathy [43], diabetic erectile 
dysfunction [44], diabetic endothelial dysfunction and atherosclerosis [45] and 
diabetic cutaneous wound healing [46]. The synergistic effect of insulin treatment 
with a EGCG protocol initiated in a preventive manner may be useful to manage 
diabetic neuropathy. 
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Table 1. Characterization of Experimental Groups 
 
Experimental 
Groups 
Blood glucose 
concentration 
(mg/dl) 
Body weight 
(g) 
Volume 
Ingestion 
(ml/day) 
Control 102±21,5 413±4,7 54±13,6 
STZ 567±17,9* 291±7,6* 258±27,6* 
STZ+EGCG 554±25,7* 288±10,2* 247±31,0* 
Mean values ± s.d. EGCG:  epigalocathechin-3-gallate; STZ: streptozotocin 
*p<0.01 (comparisons with control group) 
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Legend of Figures 
 
Fig 1- Effects of EGCG treatment on mechanical hyperalgesia (A) and tactile 
allodynia using the paw-pressure and the von Frey tests, respectively. Paw 
withdrawal thresholds (PWT) in control animals, STZ-diabetic rats (STZ group) 
and STZ-diabetic rats treated with EGCG (STZ+EGCG), before diabetes induction 
(w 0) and at 10 weeks of disease (w 10). The antioxidant treatment with EGCG 
ameliorated mechanical hyperalgesia and mechanical allodyinia, but without 
normalization to control levels. Significance of symbols: * - p<0.05; ** - p <0.01. 
 
Fig 2- Effects of EGCG treatment on oxidative stress damage at the superficial 
dorsal horn (laminae I-III) of the spinal cord. (A) Optical density of 8-OHdG, a 
marker of nucleic-acid oxidative stress damage in control animals, STZ-diabetic 
rats with 10 weeks of disease (STZ group) and STZ-diabetic rats treated with 
EGCG (STZ+EGCG group). (B-D) Representative photomicrographs of L4 spinal 
cord sections after immunoreaction for 8-OHdG in control (B), STZ (C) and STZ+ 
EGCG (D) groups. The STZ group presents a significant increase in the 
expression of 8-OHdG when compared with control animals. Treatment with 
EGCG fully prevented the diabetes-induced oxidative stress damage to control 
levels. Scale bars: 100µm; scale bar of insert: 25µm. Significance of symbols: * - 
p<0.05; ** - p <0.01. 
 
 
Fig 3- Effects of EGCG treatment on neuronal activity at the superficial dorsal dorn 
(laminae I-III) of the spinal cord (A) Mean number of Fos-IR neurons per section in 
! #*!
control animals, STZ-diabetic with 10 weeks of disease (STZ group) and STZ-
diabetic rats treated with EGCG (STZ+EGCG). B-D are representative 
immunofluorescence photomicrographs in sections from control (B), STZ (C) and 
STZ+ EGCG (D) groups. The number of Fos-IR neurons is markedly increased in 
the STZ group in comparison with the control group and that increase was 
prevented by the EGCG treatment. Significance of symbols: ** p< 0.01. Scale bar 
in D: 100µm (all photomicrographs are at the same magnification).  
 
Fig 4- Effects of EGCG treatment on co-localization of 8-OHdG and Fos in the 
superficial dorsal horn (laminae I-III) of the spinal cord. (A) Percentage of 8-OHdG-
IR cells also Fos-IR in control animals, STZ-diabetic with 10 weeks of disease 
(STZ group) and STZ-diabetic rats treated with EGCG (STZ+8-OHdG group). The 
percentage of 8-OHdG-IR that are also Fos-IR was higher the STZ group when 
compared to the control group and that increase was prevented by the treatment 
with EGCG. B-D are representative immunofluorescence photomicrographs of the 
same spinal section depicting 8-OHdG immunoreaction (B), Fos-immunostaining 
(C) or both (D) in a section of a STZ-diabetic rat. Four neurons double-
immunostained for 8-OHdG and Fos are marked with arrows in D. Significance of 
symbols: ** p< 0.01. Scale bar in D: 20µm (all photomicrographs are at the same 
magnification).! !!!!!!!!!!
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